Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.48 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.48 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11922812 | 0.86 | EPHX2 (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL1677567 | 0.86 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL3188537 | 0.85 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| Hydrochloric Acid SCHEMBL1677960 | 0.85 | EPHX2 (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4562108 | 0.85 | EPHX2 (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1567819 | 0.83 | EPHX2 (0.58) | EPHX2CNR2 | |
| SCHEMBL1149892 | 0.83 | EPHX2 (0.58) | EPHX2CNR2 | |
| Hydrochloric Acid SCHEMBL1677599 | 0.81 | EPHX2 (0.57) | EPHX2CNR2 | |
| SCHEMBL1082075 | 0.80 | EPHX2 (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1548214 | 0.80 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4107198-B1 | POLYISOCYANATE PREPARATIONS | COVESTRO DEUTSCHLAND AG (DE) | 2024-03-13 | — | — | EP | disclosed |
| EP-3560975-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-12-06 | — | — | EP | disclosed |
| EP-3724251-B2 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364030-A1 | PARENTERAL TREATMENTS INVOLVING AMINOADAMANTANE DERIVATIVES | SHINKEI THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11707439-B2 | Parenteral treatments involving aminoadamantane derivatives | SHINKEI THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3851472-B1 | IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT | COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20200315991-A1 | PARENTERAL TREATMENTS INVOLVING AMINOADAMANTANE DERIVATIVES | SHINKEI THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| US-8129519-B2 | Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof | ALLERGAN SALES, LLC | 2012-03-06 | — | — | US | disclosed |
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | ALLERGAN SALES, LLC | 2010-06-03 | — | — | US | disclosed |
| EP-1889832-A2 | Oxypentafluorosulfate compositions and processes for making them | Air Products and Chemicals, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137354-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | WNT1, CTNND1, CTNNB1 | GRIN2D 4626/4885GRIN3B 4785/4885GRIN1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.